Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 4377 - 4384 of 12142 results

“When You Promise Security, You Need to Deliver Security”
April 13, 2020| Blog| Viewpoint

Fed To Add COVID-19 as Essential New Element to Bank Stress Tests
April 13, 2020| Blog| Viewpoint

NYSE Temporarily Eases Certain Continued Listing and Shareholder Approval Requirements as a Result of Coronavirus (COVID-19)
April 13, 2020| Advisory| Viewpoint

Celgene v. Sun Pharma Global: Satisfying Subject Matter Jurisdiction Under § 271(e)(2)
April 13, 2020| Blog| Viewpoint

FinCEN Addresses the CARES Act, Suspends Implementation of CTR Filing Changes, and Offers COVID-19 Online Contact Mechanism
April 10, 2020| Blog| Viewpoint

U.S. Senate Explores Use of Big Data To Fight COVID-19
April 10, 2020| Blog| Viewpoint

Massachusetts Attorney General Sets Her Sights on Debt Collectors in the Wake of COVID-19
April 10, 2020| Blog| Viewpoint

Middle Market Private Equity Fund Strategies for Managing Portfolio Company Defaults
April 10, 2020| Advisory| Viewpoint
News & Press Releases
Mintz Advises Point72 and Tsunami Express Car Wash in Acquisition of 53 Car Wash Locations from Whistle Express Car Wash
September 16, 2025
Mintz advised Point72 and Tsunami Express Car Wash, its portfolio company, in Tsunami’s acquisition of 53 car wash locations from Whistle Express Car Wash, which is owned by affiliates of Oaktree Capital Management.
Mintz Advises Charlesbank Capital Partners on Acquisition of Q6 Cyber
September 15, 2025
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025
Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”
Events
Podcasts

Mintz On Air: Practical Policies – DEI Developments: The Proxy Problem
September 16, 2025| Podcast|

Mintz On Air: Practical Policies – Disparage Me Not
August 26, 2025| Podcast|

Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|
